Research programme: immunological disorder therapeutics - Schrodinger
Latest Information Update: 08 Dec 2023
At a glance
- Originator Schrodinger
- Class Small molecules
- Mechanism of Action NLRP3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Immunological disorders
Most Recent Events
- 03 Oct 2023 Early research in Immunological disorders in USA (unspecified route) prior to October 2023 (Schrodinger pipeline, October 2023)